147 related articles for article (PubMed ID: 18214711)
1. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients.
Masurel-Paulet A; Poggi-Bach J; Rolland MO; Bernard O; Guffon N; Dobbelaere D; Sarles J; de Baulny HO; Touati G
J Inherit Metab Dis; 2008 Feb; 31(1):81-7. PubMed ID: 18214711
[TBL] [Abstract][Full Text] [Related]
2. Natural Protein Tolerance and Metabolic Control in Patients with Hereditary Tyrosinaemia Type 1.
Yilmaz O; Daly A; Pinto A; Ashmore C; Evans S; Gupte G; Santra S; Preece MA; Mckiernan P; Kitchen S; Ayhan NY; MacDonald A
Nutrients; 2020 Apr; 12(4):. PubMed ID: 32325917
[TBL] [Abstract][Full Text] [Related]
3. Recommendations for the management of tyrosinaemia type 1.
de Laet C; Dionisi-Vici C; Leonard JV; McKiernan P; Mitchell G; Monti L; de Baulny HO; Pintos-Morell G; Spiekerkötter U
Orphanet J Rare Dis; 2013 Jan; 8():8. PubMed ID: 23311542
[TBL] [Abstract][Full Text] [Related]
4. Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia.
Pankowicz FP; Barzi M; Legras X; Hubert L; Mi T; Tomolonis JA; Ravishankar M; Sun Q; Yang D; Borowiak M; Sumazin P; Elsea SH; Bissig-Choisat B; Bissig KD
Nat Commun; 2016 Aug; 7():12642. PubMed ID: 27572891
[TBL] [Abstract][Full Text] [Related]
5. Decoding hepatorenal tyrosinemia type 1: Unraveling the impact of early detection, NTBC, and the role of liver transplantation.
Kehar M; Sen Sarma M; Seetharaman J; Jimenez Rivera C; Chakraborty P
Can Liver J; 2024 Feb; 7(1):54-63. PubMed ID: 38505790
[TBL] [Abstract][Full Text] [Related]
6. Adult female with severe decompensation of tyrosinaemia type 1 that responds to heme treatment.
Casademunt-Gras E; Ramos A; Ruiz S; Martin M; Joaquín C
Endocrinol Diabetes Nutr (Engl Ed); 2023 Nov; 70(9):612-613. PubMed ID: 37996204
[No Abstract] [Full Text] [Related]
7. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec.
Larochelle J; Alvarez F; Bussières JF; Chevalier I; Dallaire L; Dubois J; Faucher F; Fenyves D; Goodyer P; Grenier A; Holme E; Laframboise R; Lambert M; Lindstedt S; Maranda B; Melançon S; Merouani A; Mitchell J; Parizeault G; Pelletier L; Phan V; Rinaldo P; Scott CR; Scriver C; Mitchell GA
Mol Genet Metab; 2012 Sep; 107(1-2):49-54. PubMed ID: 22885033
[TBL] [Abstract][Full Text] [Related]
8. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).
Holme E; Lindstedt S
J Inherit Metab Dis; 1998 Aug; 21(5):507-17. PubMed ID: 9728331
[TBL] [Abstract][Full Text] [Related]
9. Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice.
Mayorandan S; Meyer U; Gokcay G; Segarra NG; de Baulny HO; van Spronsen F; Zeman J; de Laet C; Spiekerkoetter U; Thimm E; Maiorana A; Dionisi-Vici C; Moeslinger D; Brunner-Krainz M; Lotz-Havla AS; Cocho de Juan JA; Couce Pico ML; Santer R; Scholl-Bürgi S; Mandel H; Bliksrud YT; Freisinger P; Aldamiz-Echevarria LJ; Hochuli M; Gautschi M; Endig J; Jordan J; McKiernan P; Ernst S; Morlot S; Vogel A; Sander J; Das AM
Orphanet J Rare Dis; 2014 Aug; 9():107. PubMed ID: 25081276
[TBL] [Abstract][Full Text] [Related]
10. Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function.
Bartlett DC; Lloyd C; McKiernan PJ; Newsome PN
J Inherit Metab Dis; 2014 Sep; 37(5):745-52. PubMed ID: 24515874
[TBL] [Abstract][Full Text] [Related]
11. Three Cases of Hereditary Tyrosinaemia Type 1: Neuropsychiatric Outcomes and Brain Imaging Following Treatment with NTBC.
Walker H; Pitkanen M; Rahman Y; Barrington SF
JIMD Rep; 2018; 40():97-103. PubMed ID: 29143197
[TBL] [Abstract][Full Text] [Related]
12. Dietary Considerations in Tyrosinemia Type I.
van Spronsen FJ; van Rijn M; Meyer U; Das AM
Adv Exp Med Biol; 2017; 959():197-204. PubMed ID: 28755197
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1.
van Ginkel WG; Rodenburg IL; Harding CO; Hollak CEM; Heiner-Fokkema MR; van Spronsen FJ
Paediatr Drugs; 2019 Dec; 21(6):413-426. PubMed ID: 31667718
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations.
Chinsky JM; Singh R; Ficicioglu C; van Karnebeek CDM; Grompe M; Mitchell G; Waisbren SE; Gucsavas-Calikoglu M; Wasserstein MP; Coakley K; Scott CR
Genet Med; 2017 Dec; 19(12):. PubMed ID: 28771246
[TBL] [Abstract][Full Text] [Related]
15. The Liver in Tyrosinemia Type I: Clinical Management and Course in Quebec.
Halac U; Dubois J; Mitchell GA
Adv Exp Med Biol; 2017; 959():75-83. PubMed ID: 28755185
[TBL] [Abstract][Full Text] [Related]
16. Confocal microscopy of corneal crystals in a patient with hereditary tyrosinemia type I, treated with NTBC.
Schauwvlieghe PP; Jaeken J; Kestelyn P; Claerhout I
Cornea; 2013 Jan; 32(1):91-4. PubMed ID: 22495034
[TBL] [Abstract][Full Text] [Related]
17. Emotional and behavioral problems, quality of life and metabolic control in NTBC-treated Tyrosinemia type 1 patients.
van Vliet K; van Ginkel WG; Jahja R; Daly A; MacDonald A; De Laet C; Vara R; Rahman Y; Cassiman D; Eyskens F; Timmer C; Mumford N; Bierau J; van Hasselt PM; Gissen P; Goyens PJ; McKiernan PJ; Wilcox G; Morris AAM; Jameson EA; Huijbregts SCJ; van Spronsen FJ
Orphanet J Rare Dis; 2019 Dec; 14(1):285. PubMed ID: 31801588
[TBL] [Abstract][Full Text] [Related]
18. Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain.
Couce ML; Sánchez-Pintos P; Aldámiz-Echevarría L; Vitoria I; Navas V; Martín-Hernández E; García-Volpe C; Pintos G; Peña-Quintana L; Hernández T; Gil D; Sánchez-Valverde F; Bueno M; Roca I; López-Ruzafa E; Díaz-Fernández C
Medicine (Baltimore); 2019 Sep; 98(39):e17303. PubMed ID: 31574857
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1).
Das AM
Appl Clin Genet; 2017; 10():43-48. PubMed ID: 28769581
[TBL] [Abstract][Full Text] [Related]
20. Long-term cognitive functioning in individuals with tyrosinemia type 1 treated with nitisinone and protein-restricted diet.
García MI; de la Parra A; Arias C; Arredondo M; Cabello JF
Mol Genet Metab Rep; 2017 Jun; 11():12-16. PubMed ID: 28377889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]